quick calcs: ems holdings of hc berlin pharma, page-6

Here is another article that I found - a bit more info to that already released.

It really looks quite good - maybe EMS management might save my portfolio from complete meltdown..




DGAP-News: HC Berlin Pharma AG listed on the Open Market of the Frankfurt Stock Exchange
HC Berlin Pharma AG / IPO

23.10.2008

Release of a Corporate News, transmitted by DGAP - a company of EquityStory AG.
The issuer / publisher is solely responsible for the content of this announcement.
—————————————————————————

Berlin, October 23, 2008 - HC Berlin Pharma AG, which is headquartered in
Berlin, is pleased to announce that as of today its shares will be traded
on the Open Market of the Frankfurt Stock Exchange (First Quotation Board).

The company has issued 11,141,000 bearer shares, each with a nominal value
of EUR 1.00. The free float amounts to 29.1 %. The management of HC Berlin
Pharma AG holds 17.0 % of the shares. Eastland Medical Systems Ltd, Perth,
Australia, has a shareholding of 18.0 % and the remaining 35.9 % is held by
other strategic investors.

EUR 8,000,000.00 of the share capital amounting to EUR 11,141,000.00 have been
raised due to a capital increase through a contribution in kind, namely the
manufacturing rights to the anti-malaria drug, ArTiMist(TM). In addition, the
share capital has been increased by a further EUR 3,091,000.00 due to two
capital increases by cash contributions.

HC Berlin Pharma AG was formed in May 2007 and has mainly specialised in
the development, manufacture and distribution of innovative pharmaceutical
products. The company has developed and patented new forms of administering
active agents that have already been tested and that promise greater
effectiveness and healing power. It has already acquired various patents
and licence rights for the manufacture and distribution of these
pharmaceutical products. The company’s main focus is currently on medicines
for the cure of malaria and nicotine addiction, but HC Berlin Pharma AG
also offers various products in other medical areas.

Potsdam was chosen as production location as it is an important part of the
region of Berlin/Brandenburg with its emphasis on science, its excellent
infrastructure for medical technology and its universities. It is here that
the company will start to produce its most important medical products,
anticipated from 2009. Official approval for these products is expected to
be issued soon. The company has already signed a number of memoranda of
understanding and distribution agreements in this connection.

Background information

Pharmaceuticals
Success in the battle against malaria

Next to AIDS, Malaria is one of the world’s biggest unsolved health
problems. According to the latest report from the World Health Organisation
(WHO) of September 18, 2008, there are 247 million registered cases of
malaria in Africa. Small children are still the biggest group dying of this
disease - more than 3,000 children a day. Only 3 % of these children have
access to artemisinine-based medicines. ArTiMist(TM) from HC Berlin Pharma AG
has been specially developed for the difficult treatment of children
suffering from malaria. HC Berlin Pharma AG is supported by the top
decision makers for African healthcare policies. The patron of the
initiative to fight malaria is Dr Kenneth Kaunda, the first president of
the Republic of Zambia.

ArTiMist(TM) is an anti-malaria drug that has been specially developed for
children and is administered in the form of a sublingual spray. This
innovative form of administering the drug allows it to enter the
bloodstream directly, without any of the active agent becoming lost in the
gastrointestinal tract. This gives it distinct advantages over conventional
drugs in tablet form. ArTiMist(TM) guarantees a high degree of effectiveness
and healing power with fewer side effects. The form of administering the
drug has been developed for areas that lack healthcare and clinics.
Misapplication and incorrect dosages are practically impossible.

ArTiMist(TM) has passed the clinical trials for phase I. Phase II of the
toxicity tests did not need to be carried out as the active agent has
already been approved. ArTiMist(TM) will shortly be entering the final phase
of clinical testing (phase III).

The medicine will probably be approved for marketing in 2009. In
cooperation with its Australian partner, Eastland Medical Systems Ltd, HC
Berlin Pharma AG has secured the manufacturing and distribution rights for
Africa, Asia and Australasia.

Malaria - a disease affecting the poor

In view of the targets agreed at the UN Millennium Summit in 2000 in the
battle against poverty, the United Nations called for some USD 3 billion to
fight malaria on concluding the UN Development Summit at the end of
September 2008. The world’s leading aid organisations reckon with around
200 million treatments each year, especially for children. However,
according to calculations made by the World Health Organisation (WHO), the
available funds only allow around 100 million cases to be treated. The
major aid organisations are therefore very interested in new and efficient
methods of treatment. Thus for 2009, HC Berlin Pharma AG has already signed
several memoranda of understanding (MoUs) in relation to orders in Asia and
Africa for the innovative anti-malaria drug, ArTiMist(TM), which are likely to
bring the company revenues of around EUR 40 million. At the new production
location at the scientific park in Potsdam Golm HC Berlin Pharma AG will
probably be producing up to 90 million ArTiMist(TM) treatments per annum from
the end of 2009.

‘Smokers, please stay outside’

More and more countries are introducing strict smoking bans in non private
areas. The second product development of HC Berlin Pharma AG reflects this
trend: NiCoSorb(TM) is an innovative nicotine substitute that takes effect
within just 20 seconds. NiCoSorb(TM) is also a sublingual spray which is more
effective than present nicotine replacement products and that lacks their
side effects. There is no health risk to the respiratory tracts and the
stomach, no passive smoking and no unpleasant smell in enclosed spaces. For
the distribution of the product the company has sales agreements for
overseas markets, such as China, amounting to 15 million units,
corresponding to revenues of some 70 - 75 million for 2009. For the
European market the company has received enquiries from drugstore chains
and tobacco wholesalers.

Medical technology
Safety at medical workplaces

A further mainstay of HC Berlin Pharma AG’s medical technology division are
internationally patented and approved systems for risk-free injections and
the taking of blood samples. These systems are now ready for industrial
production. The need for safe syringes is particularly great in view of the
spread of AIDS, which is often transmitted by unsafe needles. The
SafeNeedle ClipOn(TM) needle system transforms traditional syringes into safe
systems. After the injection, the needle is withdrawn into a ClipOn(TM)
syringe through the simple pressure of a finger. This ensures that the
finger does not come into contact with the contaminated tip of the needle.
In addition to its low cost, the great advantage of the new needle system
is its extreme safety and easy application. The products of the Safe Needle
Division have already been granted CE approval. They are already being
produced in Australia and successfully sold in clinics in Australia and the
UK (NHS). The company expects sales of some 40 million needle systems in
2009, corresponding to revenues of around EUR 10 million.

ClipOn(TM) is the name of the brand for human medicine. In the market for
veterinary medicine this product is called VetLok(TM), although the product’s
specific features and benefits are identical.

Child resistant and tamper evident packaging

Safety is also of prime importance when it comes to the packaging of
medicines. They must be tamper evident and stored out of the reach of
children. HC Berlin Pharma AG has developed innovative packaging solutions
that meet these requirements, on the basis of more than 15 patents. The
company expects royalties in this area to amount to some EUR 1.5 million as
early as in 2009.

A further product group from the medical technology division are sterile
wraps and pocket packaging marketed under the MediSheet(TM) trademark. They
are CE approved and are being successfully marketed in Australia, the Fat
East and the Middle East. The emphasis is on sterility in the operating
theatre and protection against multi-resistant germs and bacteria in
hospitals. HC Berlin Pharma AG has secured the marketing rights for Europe
and anticipates a market share of around 1.5 % in the first year,
corresponding to revenues of some EUR 7.5 million in this segment.

Many years of experience coupled with innovative products

The CEO of HC Berlin Pharma AG is Ottmar W. Geiger, who has many years of
experience in managing various development aid projects in South East Asia.
In addition, Mr Geiger was also President and CEO of the organisation,
Arbeiterwohlfahrt (AWO) in Potsdam for many years and responsible for
setting up and managing comprehensive, personnel-intensive facilities in
social welfare. The supervisory board is made up of persons of
international repute with a dense international network in the field of
pharmaceuticals and contacts to important decision-makers, particularly on
the African continent.

‘We have already achieved a great deal in our company’s short history and
have been able to secure the patents and manufacturing rights for a number
of promising pharmaceutical products. The listing on the Open Market is
intended to provide us with additional funding, which will particularly
allow us to launch our anti-malaria drug, ArTiMist(TM), in a very attractive
market,’ says Ottmar W. Geiger, CEO of HC Berlin Pharma AG. ‘Our portfolio
contains important products for global markets and we are convinced that
our philosophy of growth and efficiency on a humanitarian basis will allow
us to successfully establish ourselves in the market,’ concludes Rudolf W.
Schötteldreier, Chairman of HC Berlin Pharma AG’s supervisory board.

Further information about HC Berlin Pharma AG can be found at
www.hcberlinpharma.ag.

For detailed information please contact our Investor Relations team
directly at:

esVedra consulting GmbH
t: +49. 89. 28 80 81 33
f: +49. 89. 28 80 81 49
[email protected]
www.esvedra-consulting.com

Disclaimer

This announcement is intended solely for general purposes and in no way
implies an invitation to buy or sell the shares of HC Berlin Pharma AG.

23.10.2008 Financial News transmitted by DGAP